Showing results (91-100 of 369) with videos related to
Sort By:
Pageof 37
Cancer Immunology, Immunotherapy : CII|February 24, 2005
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancerSusan F Slovin, Govind Ragupathi, Cristina Musselli, et al.ESMO Open|November 13, 2020
Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancerArpit Rao, Howard I Scher, Peter De Porre, et al.Nature Reviews. Urology|February 21, 2018
Clinical implications of PTEN loss in prostate cancerTamara Jamaspishvili, David M Berman, Ashley E Ross, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failureAlexandra J Stewart, Howard I Scher, Ming-Hui Chen, et al.European Urology|August 31, 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trialFred Saad, Johann de Bono, Neal Shore, et al.Magnetic Resonance in Medicine|November 25, 2004
Imaging therapeutic response in human bone marrow using rapid whole-body MRIDouglas Ballon, Richard Watts, Jonathan P Dyke, et al.Scientific Reports|May 19, 2016
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) miceAnki Knutsson, Sabrina Hsiung, Selvi Celik, et al.Vaccine|December 19, 2012
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancerSusan F Slovin, Marissa Kehoe, Robert Durso, et al.European Urology Oncology|August 15, 2019
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 TrialsGuru P Sonpavde, Gregory R Pond, Karim Fizazi, et al.Cancer|March 29, 2002
HER-2 profiling and targeting in prostate carcinomaMichael J Morris, Victor E Reuter, W Kevin Kelly, et al.Pageof 37